[Market Focus] Abpro Bio Surges on News of Preclinical Presentation at U.S. Conference

As of 9:30 a.m. on November 5, shares of Abpro Bio on the KOSDAQ market were trading at 243 won, up 29.95% from the previous closing price. This surge appears to be driven by news that the results of a preclinical study on a substance being co-developed with Celltrion will be presented at a U.S. academic conference.

On this day, Abpro Holdings, the U.S. subsidiary of Abpro Bio, announced that the preclinical study results for the HER2×CD3 bispecific antibody candidate ABP-102/CT-P72, which is being co-developed with Celltrion, have been selected for an oral presentation at the "The Horizon" session of the Society for Immunotherapy of Cancer (SITC 2025), which will be held in the United States starting November 6.

According to the company, ABP-102/CT-P72 demonstrated strong antitumor activity and excellent safety results in various HER2-high-expressing tumor models, including an Enhertu-resistant model, during preclinical studies.

Originally a machine tool company, Eugene Tech changed its name to Abpro Bio in August 2019. In October of the same year, it acquired the pipeline intellectual property rights and commercialization rights for assets under development by Abpro Corporation (now Abpro Holdings) based in Massachusetts, USA. In November 2019, the company established Abpro Bio International, a U.S. corporation, and acquired controlling shares of Abpro Corporation.